Human embryonic stem cell-derived cardiomyocyte platform screens inhibitors of SARS-CoV-2 infection.
Commun Biol
; 4(1): 926, 2021 07 29.
Article
em En
| MEDLINE
| ID: mdl-34326460
ABSTRACT
Patients with cardiovascular comorbidities are more susceptible to severe infection with SARS-CoV-2, known to directly cause pathological damage to cardiovascular tissue. We outline a screening platform using human embryonic stem cell-derived cardiomyocytes, confirmed to express the protein machinery critical for SARS-CoV-2 infection, and a SARS-CoV-2 spike-pseudotyped virus system. The method has allowed us to identify benztropine and DX600 as novel inhibitors of SARS-CoV-2 infection in a clinically relevant stem cell-derived cardiomyocyte line. Discovery of new medicines will be critical for protecting the heart in patients with SARS-CoV-2, and for individuals where vaccination is contraindicated.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Antivirais
/
Miócitos Cardíacos
/
Avaliação Pré-Clínica de Medicamentos
/
Células-Tronco Embrionárias Humanas
/
SARS-CoV-2
Limite:
Humans
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article